Local News

• Scientists in Spain develop new methods for monitoring drug abuse  Scientists at the Spanish Council for Scientific Research in Barcelona have developed a new method for monitoring the consumption of drugs of abuse in the general population. This method was was developed using analytical laboratory technology from Applied Biosystems/MDS Analytical Technologies.
  Applied Biosystems May 15, 2008  
• IDM Pharma announces updated data from mifamurtide compassionate access program  IDM Pharma announced the presentation of updated data from a compassionate access program evaluating mifamurtide (L-MTP-PE) in patients with lung metastases as a result of the progression of osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.
  IDM Pharma, Inc. May 15, 2008  
• VIA Pharmaceuticals completes enrollment in Phase 2 Acute Coronary Syndrome (ACS) trial  VIA Pharmaceuticals announced that it has completed patient enrollment in its acute coronary syndrome (ACS) study. The ACS study is one of three Phase 2 trials investigating VIA-2291, the company's lead product candidate in cardiovascular disease.
  VIA Pharmaceuticals, Inc. May 15, 2008  
• Spectranetics introduces device for removal of non-functional and infected cardiac leads  Spectranetics Corporation announced the availability of the new LLD EZ Lead Locking Device for the removal of non-functional or infected pacing and defibrillation leads. The LLD EZ enables physicians to secure the entire lead creating traction to enable the removal process.
  Spectranetics Corporation May 15, 2008  
• Wyeth's major depressive disorder treatment Pristiq now available in U.S. pharmacies  Wyeth Pharmaceuticals announced that PRISTIQ(TM), a new serotonin-norepinephrine reuptake inhibitor approved to treat adult patients with major depressive disorder, is now available in U.S. retail pharmacies nationwide. The recommended dose of PRISTIQ is 50 milligrams (mg) once daily.
  Wyeth May 15, 2008  
• FDA approves AstraZeneca’s Seroquel for maintenance treatment in bipolar disorder  AstraZeneca announced that the U.S. Food and Drug Administration has approved SEROQUEL(R) (quetiapine fumarate) for the maintenance treatment of patients with bipolar I disorder, as adjunct to lithium or divalproex.
  AstraZeneca May 14, 2008  
• DuPont and Genencor create world-leading cellulosic ethanol company  DuPont and Genencor announced an agreement to form DuPont Danisco Cellulosic Ethanol, a 50/50 global joint venture to develop and commercialize the leading, low-cost technology solution for the production of cellulosic ethanol to address a $75 billion global market opportunity.
  Genencor May 14, 2008  
• F.D.A. chief writes Congress for money  After being pummeled for weeks on Capitol Hill over the president's budget, Food and Drug Commissioner Andrew C. von Eschenbach has written Congress that the agency needs an immediate infusion of $275 million to ensure that imported foods, drugs and medical devices are safe.
  The New York Times May 14, 2008  Gardiner Harris
• Lilly employees from nearly 50 nations participate in first-ever Global Day of Service  Thousands of Eli Lilly and Company employees in nearly 50 nations are rolling up their sleeves to help address local community needs in celebration of Lilly's first-ever Global Day of Service, possibly the largest corporate volunteer initiative to ever take place on one day.
  Eli Lilly and Company May 14, 2008  
• BioLife Solutions announces FDA Master File Acceptance for CryoStor™  BioLife Solutions, a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells, tissues, and organs, today announced that its Master File for CryoStor cryopreservation media has been accepted by the US Food and Drug Administration (FDA).
  BioLife Solutions Inc. May 14, 2008  

   (next 10 articles)